Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1863P - Impact of systemic treatment versus best supportive care on survival in patients older than 80 years with cancer

Date

17 Sep 2020

Session

E-Poster Display

Topics

Supportive Care and Symptom Management

Tumour Site

Presenters

Alejandro Olivares Hernandez

Citation

Annals of Oncology (2020) 31 (suppl_4): S988-S1017. 10.1016/annonc/annonc291

Authors

A. Olivares Hernandez1, R.A. Escala Cornejo2, L. Figuero Pérez3, M.D.R. Vidal Tocino3, J. Claros Ampuero3, E. Escalera Martín3, Á. López Gutiérrez3, E. Terán Brage3, A. Amores Martín3, C.A. Rodríguez Sáchez3, B. Barrios Collado3, I. Toribio García4, J.P. Miramontes-González5, J.J. Cruz Hernández3

Author affiliations

  • 1 Medical Oncology Dept, IBSAL - Instituto de Investigación Biomédica de Salamanca, 37007 - Salamanca/ES
  • 2 Medical Oncology Department, Complejo Asistencial de Avila - Hospital Nuestra Senora de Sonsoles Urgencias, 05071 - Ávila/ES
  • 3 Medical Oncology, University Hospital of Salamanca, 37007 - Salamanca/ES
  • 4 Internal Medicine, University Hospital of Salamanca, 37007 - Salamanca/ES
  • 5 Internal Medicine, University Hospital Río Hortega, 47012 - Valladolid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1863P

Background

Seventy percent of cancer types are diagnosed in people over 65 years old. These data suggest a great challenge in the management of these patients (pts), and the optimisation of treatment in this population is a priority. As the age of patients progresses, best supportive care (BSC) measures become a very valid option, and systemic treatments (STs) are more controversial. Accordingly, the aim of this study is to analyse the impact of systemic treatment compared to BSC regarding survival in cancer pts over 80.

Methods

A retrospective study of pts over 80 diagnosed with cancer between 2016 and 2018 was conducted at the University Healthcare Complex of Salamanca. Pts were divided into two cohorts according to the therapeutic strategy received, BSC or STs. Survival analysis was performed with the Kaplan−Meier and Cox regression method using SPSS v. 26 software. Statistical significance was established by p <0.01.

Results

A total of 398 pts were included: 213 (53.5%) men and 185 (46.5%) women. The median age was 87 years. In the group that received BSC (180/398, 45.2%), the median overall survival (OS) was 3 months versus 55 months in pts who received STs (218/398, 54.8%) (HR = 0.12 [95% CI 0.089-0.162]; p <0.001). One hundred and ninety-six pts (49.2%) were diagnosed in the early stage (ES) or locally advanced (LA), and 202 pts (50.8%) were diagnosed at the advanced stage. When the two cohorts were analysed considering the stages, the OS of pts with ES or LA who received BSC compared to STs was 5 months versus 60 months (HR = 0.118 [95% CI 0.068-0.207]; p <0.001). In advanced stages, the OS for BSC versus STs was 3 months versus 22 months (HR = 0.312 [95% CI 0.206-0.474]; p <0.001), respectively. Within STs, chemotherapy in pts with advanced stages demonstrated an OS of 15 months versus 3 months in the BSC group (HR = 0.329 [95% CI 0.157-0.690]; p = 0.001).

Conclusions

Based on the results of our study, STs in the elderly population are associated with a significant increase in survival compared to BSC alone. A multidisciplinary assessment with geriatric counselling is essential for the initiation of cancer treatments in elderly pts. Therefore, more studies on cancer treatments are needed in this group of pts.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.